HK1207403A1 - Biomarkers to identify patients that will respond to treatment and treating such patients - Google Patents
Biomarkers to identify patients that will respond to treatment and treating such patientsInfo
- Publication number
- HK1207403A1 HK1207403A1 HK15108041.5A HK15108041A HK1207403A1 HK 1207403 A1 HK1207403 A1 HK 1207403A1 HK 15108041 A HK15108041 A HK 15108041A HK 1207403 A1 HK1207403 A1 HK 1207403A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- patients
- biomarkers
- respond
- treating
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261635336P | 2012-04-19 | 2012-04-19 | |
US201261664471P | 2012-06-26 | 2012-06-26 | |
US201361778260P | 2013-03-12 | 2013-03-12 | |
PCT/US2013/037355 WO2013158984A1 (en) | 2012-04-19 | 2013-04-19 | Biomarkers to identify patients that will respond to treatment and treating such patients |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1207403A1 true HK1207403A1 (en) | 2016-01-29 |
Family
ID=49384103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108041.5A HK1207403A1 (en) | 2012-04-19 | 2015-08-19 | Biomarkers to identify patients that will respond to treatment and treating such patients |
Country Status (5)
Country | Link |
---|---|
US (2) | US9663825B2 (xx) |
EP (1) | EP2839037B1 (xx) |
JP (2) | JP2015515279A (xx) |
HK (1) | HK1207403A1 (xx) |
WO (1) | WO2013158984A1 (xx) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
LT2526093T (lt) | 2010-01-22 | 2016-10-10 | Acetylon Pharmaceuticals, Inc. | Grįžtamieji amido junginiai kaip baltymo deacetilazės inhibitoriai ir jų panaudojimo būdai |
PL2640709T3 (pl) | 2010-11-16 | 2016-10-31 | Związki pirymidynohydroksyamidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania” | |
CN103476796A (zh) | 2011-01-28 | 2013-12-25 | 赛诺菲 | 治疗特定受试者组的方法中使用的针对pcsk9的人抗体 |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
EP3536712B1 (en) | 2011-09-16 | 2023-05-31 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) |
US9663825B2 (en) | 2012-04-19 | 2017-05-30 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
AU2013202506B2 (en) * | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
EA201592267A1 (ru) | 2013-06-07 | 2016-04-29 | Ридженерон Фармасьютикалз, Инк. | Способы ингибирования атеросклероза посредством введения ингибитора pcsk9 |
JP6626437B2 (ja) | 2013-10-08 | 2019-12-25 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | ヒストンデアセチラーゼ阻害剤とHer2阻害剤またはPI3K阻害剤のいずれかの組み合わせ |
ES2862126T3 (es) | 2013-10-10 | 2021-10-07 | Acetylon Pharmaceuticals Inc | Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa |
EP4137135B1 (en) | 2013-10-24 | 2024-06-05 | Mayo Foundation for Medical Education and Research | Treatment of polycystic diseases with an hdac6 inhibitor |
AU2014348765A1 (en) | 2013-11-12 | 2016-06-09 | Regeneron Pharmaceuticals, Inc. | Dosing regimens for use with PCSK9 inhibitors |
EP3076973B1 (en) | 2013-12-03 | 2020-04-29 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
WO2015095632A1 (en) * | 2013-12-20 | 2015-06-25 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma |
US10890587B2 (en) * | 2014-01-28 | 2021-01-12 | Quest Diagnostics Investments Incorporated | Method and compositions for detecting an adenoma-adenocarcinoma transition in cancer |
GB2530470A (en) | 2014-04-17 | 2016-03-30 | Imp Innovations Ltd | Methods |
BR112017000301A2 (pt) * | 2014-07-07 | 2017-11-07 | Acetylon Pharmaceuticals Inc | tratamento de leucemia com inibidores de histona desacetilase |
JP2017528427A (ja) | 2014-07-16 | 2017-09-28 | サノフィ・バイオテクノロジー | ヘテロ接合性家族性高コレステロール血症(heFH)を有する患者を処置するための方法 |
US20170234881A1 (en) * | 2014-09-05 | 2017-08-17 | Inserm ( Institut National De La Santé Et De La Recherche Médicale) | Methods of diagnosing and treating cancer |
JP2017537164A (ja) | 2014-12-05 | 2017-12-14 | ユニヴァーシティ・オブ・モデナ・アンド・レッジョ・エミリア | リンパ腫の治療に使用されるヒストン脱アセチル化酵素阻害剤とベンダムスチンとの組み合わせ |
CN107835810A (zh) | 2014-12-12 | 2018-03-23 | 瑞格纳西制药有限公司 | 作为hdac1/2抑制剂的哌啶衍生物 |
US20160339022A1 (en) * | 2015-04-17 | 2016-11-24 | Acetylon Pharmaceuticals Inc. | Treatment of neuroblastoma with histone deacetylase inhibitors |
US11478457B2 (en) | 2015-04-23 | 2022-10-25 | Nutech Ventures | Castration-resistant prostate cancer |
PT3297992T (pt) | 2015-05-22 | 2020-03-17 | Chong Kun Dang Pharmaceutical Corp | Compostos derivados de alquilo heterocíclicos como inibidores seletivos da histona desacetilase e composições farmacêuticas que compreendem os mesmos |
CA2988594C (en) | 2015-06-08 | 2023-08-15 | Acetylon Pharmaceuticals, Inc. | Methods of making protein deacetylase inhibitors |
US10464906B2 (en) | 2015-06-08 | 2019-11-05 | Acetylon Pharmaceuticals, Inc. | Crystalline forms of a histone deacetylase inhibitor |
CN107922507B (zh) | 2015-08-18 | 2022-04-05 | 瑞泽恩制药公司 | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 |
JP2019515909A (ja) | 2016-04-19 | 2019-06-13 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物 |
JP7233220B2 (ja) * | 2016-06-09 | 2023-03-06 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Hdac阻害剤とbet阻害剤の使用方法及びその薬学的組み合わせ |
WO2018031472A1 (en) | 2016-08-08 | 2018-02-15 | Acetylon Pharmaceuticals Inc. | Pharmaceutical combinations of histone deacetylase 6 inhibitors and cd20 inhibitory antibodies and uses thereof |
JP7090611B2 (ja) | 2016-11-23 | 2022-06-24 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド1(pd-l1)阻害剤とを含む医薬組み合わせ物及びその使用方法 |
CN106822869B (zh) * | 2017-03-16 | 2020-10-30 | 北京热休生物技术有限公司 | DEF8蛋白的多肽与热休克蛋白gp96的复合物在制备治疗与预防癌症药物中的应用 |
KR102016217B1 (ko) * | 2017-09-29 | 2019-08-29 | 사회복지법인 삼성생명공익재단 | 소화기암 환자의 면역치료 반응성 예측용 cish 마커 및 이의 용도 |
CN113226354A (zh) * | 2018-06-26 | 2021-08-06 | 得克萨斯大学体系董事会 | 用于调节免疫应答的方法和组合物 |
JP2023532199A (ja) * | 2020-06-17 | 2023-07-27 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | プロテアソーム阻害剤治療のためのバイオマーカーに基づく患者選択 |
IL307883A (en) | 2021-04-23 | 2023-12-01 | Tenaya Therapeutics Inc | HDAC6 inhibitors for use in the treatment of dilated myocardial disease |
EP4333841A1 (en) | 2021-05-04 | 2024-03-13 | Tenaya Therapeutics, Inc. | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
CN113341156B (zh) * | 2021-06-01 | 2022-02-22 | 中国医学科学院北京协和医院 | 鉴别卵巢子宫内膜异位症/卵巢癌的试剂及其应用 |
CN116637122B (zh) * | 2023-07-20 | 2023-10-10 | 呈诺再生医学科技(北京)有限公司 | 环状RNA circ-DCUN1D4在肝癌诊断和治疗中的新用途 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003035843A2 (en) | 2001-10-25 | 2003-05-01 | Buck Institute For Age Research | Screening system for modulators of her2 mediated transcription and her2 modulators identifed thereby |
JPWO2004074478A1 (ja) * | 2003-02-19 | 2006-06-01 | アステラス製薬株式会社 | ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法 |
EP1491188A1 (en) | 2003-06-25 | 2004-12-29 | G2M Cancer Drugs AG | Topical use of valproic acid for the prevention or treatment of skin disorders |
CN101495116A (zh) | 2005-03-22 | 2009-07-29 | 哈佛大学校长及研究员协会 | 蛋白降解病症的治疗 |
US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
CA2631236C (en) | 2005-12-01 | 2019-10-29 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
EP1963862A4 (en) * | 2005-12-05 | 2010-03-03 | Merck & Co Inc | METHODS FOR PREDICTING REACTION TO TREATMENT FROM EXPRESSION PROFILES OF PROTEIN AND TRANSCRIPTIONAL BIOMARKERS |
RU2456990C2 (ru) | 2006-09-15 | 2012-07-27 | Янссен Фармацевтика Нв | Комбинации специфичных ингибиторов гистоновых деацетилаз класса i с ингибиторами протеасом |
NZ579048A (en) * | 2007-01-30 | 2012-05-25 | Pharmacyclics Inc | Methods for determining cancer resistance to histone deacetylase inhibitors |
LT2526093T (lt) | 2010-01-22 | 2016-10-10 | Acetylon Pharmaceuticals, Inc. | Grįžtamieji amido junginiai kaip baltymo deacetilazės inhibitoriai ir jų panaudojimo būdai |
WO2012018499A2 (en) | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
PL2640709T3 (pl) | 2010-11-16 | 2016-10-31 | Związki pirymidynohydroksyamidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania” | |
US9663825B2 (en) | 2012-04-19 | 2017-05-30 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
WO2014121062A1 (en) | 2013-02-01 | 2014-08-07 | Acetylon Pharmaceuticals, Inc. | Selective hdac3 inhibitors |
US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
EP3004141A4 (en) | 2013-06-03 | 2017-05-31 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase ( hdac) biomarkers in multiple myeloma |
EP3046559A4 (en) | 2013-09-20 | 2017-03-22 | Acetylon Pharmaceuticals, Inc. | Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitor |
JP6626437B2 (ja) | 2013-10-08 | 2019-12-25 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | ヒストンデアセチラーゼ阻害剤とHer2阻害剤またはPI3K阻害剤のいずれかの組み合わせ |
WO2015054197A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma |
ES2862126T3 (es) | 2013-10-10 | 2021-10-07 | Acetylon Pharmaceuticals Inc | Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa |
ES2818933T3 (es) | 2013-10-10 | 2021-04-14 | Acetylon Pharmaceuticals Inc | Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin |
WO2015054175A1 (en) | 2013-10-11 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deactylase inhibitors and immunomodulatory drugs |
EP3076973B1 (en) | 2013-12-03 | 2020-04-29 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
WO2015095632A1 (en) | 2013-12-20 | 2015-06-25 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma |
US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
BR112017000301A2 (pt) | 2014-07-07 | 2017-11-07 | Acetylon Pharmaceuticals Inc | tratamento de leucemia com inibidores de histona desacetilase |
WO2016057779A2 (en) | 2014-10-08 | 2016-04-14 | Acetylon Pharmaceuticals, Inc. | Induction of gata2 by hdac1 and hdac2 inhibitors |
US20160158231A1 (en) | 2014-12-05 | 2016-06-09 | Vib Vzw | Pyrimidine hydroxy amide compounds for treating peripheral neuropathy |
CN107835810A (zh) | 2014-12-12 | 2018-03-23 | 瑞格纳西制药有限公司 | 作为hdac1/2抑制剂的哌啶衍生物 |
US20160339022A1 (en) | 2015-04-17 | 2016-11-24 | Acetylon Pharmaceuticals Inc. | Treatment of neuroblastoma with histone deacetylase inhibitors |
US10272084B2 (en) | 2015-06-01 | 2019-04-30 | Regenacy Pharmaceuticals, Llc | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy |
CA2988594C (en) | 2015-06-08 | 2023-08-15 | Acetylon Pharmaceuticals, Inc. | Methods of making protein deacetylase inhibitors |
US10464906B2 (en) | 2015-06-08 | 2019-11-05 | Acetylon Pharmaceuticals, Inc. | Crystalline forms of a histone deacetylase inhibitor |
-
2013
- 2013-04-19 US US13/866,367 patent/US9663825B2/en active Active
- 2013-04-19 JP JP2015507216A patent/JP2015515279A/ja active Pending
- 2013-04-19 WO PCT/US2013/037355 patent/WO2013158984A1/en active Application Filing
- 2013-04-19 EP EP13778809.7A patent/EP2839037B1/en active Active
-
2015
- 2015-08-19 HK HK15108041.5A patent/HK1207403A1/xx unknown
-
2017
- 2017-04-26 US US15/497,397 patent/US10648038B2/en active Active
-
2019
- 2019-02-04 JP JP2019017767A patent/JP6906554B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US10648038B2 (en) | 2020-05-12 |
EP2839037B1 (en) | 2018-12-26 |
US20140011767A1 (en) | 2014-01-09 |
WO2013158984A1 (en) | 2013-10-24 |
JP2019076114A (ja) | 2019-05-23 |
JP6906554B2 (ja) | 2021-07-21 |
EP2839037A1 (en) | 2015-02-25 |
JP2015515279A (ja) | 2015-05-28 |
US20170327895A1 (en) | 2017-11-16 |
US9663825B2 (en) | 2017-05-30 |
EP2839037A4 (en) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1207403A1 (en) | Biomarkers to identify patients that will respond to treatment and treating such patients | |
HK1212239A1 (en) | Methods for prevention and treatment of preeclampsia | |
EP2906143A4 (en) | SYSTEM AND METHOD FOR CARDIAC TREATMENT | |
TWI560299B (en) | Surface treatment for stainless steel and housing made thereby | |
BR112014031806A2 (pt) | método para tratamento de câncer positivo para gd2 | |
EP2874647A4 (en) | METHOD FOR DIAGNOSIS AND TREATMENT | |
EP2911753A4 (en) | THERAPY DEVICE FOR PINE CLAMP PREPARATION AND TREATMENT | |
GB201217296D0 (en) | Method of treatment and/or prevention | |
EP2867239A4 (en) | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | |
HK1214355A1 (zh) | 用於治療和/或限制糖尿病發展的方法 | |
HK1207004A1 (en) | Treatment of mild and moderated alzheimers disease | |
ZA201501503B (en) | Bio-inoculant and use thereof for treatment of effluents | |
EP2789289A4 (en) | ENDOSCOPE DEVICE AND TREATMENT DEVICE | |
ZA201404067B (en) | Water treatment device and method | |
EP2760161A4 (en) | METHOD AND DEVICE FOR PROCESSING POLICY | |
GB201204981D0 (en) | Pre-harvest treatment | |
HK1212999A1 (zh) | 用於治療和/或限制糖尿病的發展的方法 | |
EP2928460A4 (en) | METHODS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY SKIN DISEASES | |
GB201213968D0 (en) | Prevention and treatment of osteoarthritis | |
HK1220396A1 (zh) | 痤瘡的治療和預防 | |
HK1210134A1 (en) | Wastewater treatment unit and method | |
ZA201503834B (en) | Identifying subjects in need of treatment | |
ZA201501068B (en) | Methods for prevention and treatment of preeclampsia | |
GB201317373D0 (en) | Treatment and prevention of cancer | |
GB201208048D0 (en) | Treatment of digestive disorder |